The results of an open-label extension study confirmed the interchangeability of biosimilar CT-917 with reference adalimumab for plaque psoriasis.

Guselkumab treatment was associated with improvements in 3 biomarkers associated with systemic inflammation among patients with plaque psoriasis.

The MACE risk associated with initiating ustekinumab is comparable to that of adalimumab, etanercept, and secukinumab in patients with PsO or PsA.

Besides knowing what different patterns of infection exist across advanced therapies, what is “really important” is how ...

Following President Trump’s announcement on Monday of an executive order to cut prescription drug prices, experts share some ...

On April 14, 2025, Celltrion, Inc. announced that the U.S. Food and Drug Administration granted an interchangeable designation to YUFLYMA (adalimumab-aaty), its biosimilar referencing HUMIRA ...

Scientists identify the complex interplay between immune dysfunction, genetics, environment and disease progression driving ...

An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Given the dramatic changes in GLP-1 and biologic treatments and their rapid adoption, real-world data illuminating patient feedback and prescriber rationale is essential.” — Chris Baker, Amplity CEO ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The "Hidradenitis Suppurativa Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's ...